BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Advan
Post# of 122
(Total Views: 170)
Posted On: 08/18/2023 5:30:21 PM
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Advances NanoAb Therapy as IL-17 Drug Candidate for Psoriasis Treatment
- Similar business model but different antibody therapies for psoriasis treatment, BiondVax uses NanoAbs while Apogee Therapeutics, Inc. uses conventional mAbs
- BiondVax NanoAbs provide superior benefits not seen in mAb therapies, including new routes of administration, higher affinity, better binding, and a higher level of stability at room temperature
- Apogee recently went public at $500 million pre-money, raising $300 million in an upsized deal, and has a $1 billion market cap – should be an eye-opener to BiondVax investors who recognize benefits of NanoAbs over mAb development
- The global psoriasis treatment market was valued at $26.13 billion in 2022 and is anticipated to reach $57.84 billion by 2031, growing at a CAGR of 9.23%
Modern-day medicine has been revolutionized and personalized to cater to more specific disease characteristics. A prime example of this innovation is monoclonal antibodies (“mAbs”) and nanosized antibodies (NanoAbs), therapeutic options that address diseases in ways other therapies cannot. Several companies are penetrating the market and a compelling comparison can be made between two – one supporting mAbs and the other NanoAbs. Both companies share similar objectives and stages of development.
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is focused on the development of NanoAbs derived from alpacas. Alpaca-derived antibodies, also called VHH-antibodies, exhibit the potential for superior biobetter therapies that could be used for a wide range of diseases. BiondVax’s current pipeline is targeting COVID-19, psoriasis, asthma, and other diseases with large unmet medical needs – with collaboration from the prestigious Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”), both in Germany.
Apogee Therapeutics (NASDAQ: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications, is focused on the development of conventional mAbs therapeutics (https://nnw.fm/azQRk ). The company’s technology approach has been shown to create antibodies with significantly extended half-life and other optimized properties. The primary enhancement that Apogee hopes to achieve through its mAb development is a slightly longer duration of benefit and slightly fewer drug administrations.
Despite the benefits that conventional mAbs offer, BiondVax’s NanoAbs may offer superior benefits that Apogee’s formulations cannot, such as:
The opportunity for new routes of administration, such as inhalation and intradermal injection – neither of which work well with traditional antibody therapies, thereby creating new market opportunities for BiondVax without competing head-to-head with existing antibody treatments
A higher affinity and better binding to the target, permitting lower dosages, fewer side effects, and lower costs overall
Stability at room temperature, unlike regular antibodies that need cold chain logistics until they are administered to the patient thus limiting where and when administration occurs
The potential benefits of BiondVax’s NanoAbs have been showcased in the company’s own pre-clinical studies, and the company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing.
Apogee and BiondVax are targeting the immune system’s IL-17 cytokine as they develop their drugs; IL-17 is involved in several diseases with BiondVax initially targeting IL-17 towards a psoriasis treatment.
The global psoriasis treatment market was valued at $26.13 billion in 2022 and is anticipated to reach $57.84 billion by 2031, growing at a CAGR of 9.23% (https://nnw.fm/w2FHQ ). The market is expected to grow at this rate due to the increased awareness of the affliction and the advancement in therapies associated with it. BiondVax’s VHH antibodies propose a different approach to treatment, which does not necessarily compete head-to-head with treatment options, but provides a unique alternative approach.
Apogee only recently went public a few weeks ago at $500 million pre-money, raising $300 million in an upsized deal, and now the company has a $1 billion market cap. BiondVax’s NanoAb advantages over Apogee’s mAbs offer an attractive prospect to investors who are looking to get in early on the “bio better” antibody movement. With huge potential and a market cap that’s currently miniscule in comparison, only about $5 million and trading under a $1.50 per share, its little wonder that Aegis Capital reiterated its buy rating with a $7 price target (https://nnw.fm/31MTL ).
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Similar business model but different antibody therapies for psoriasis treatment, BiondVax uses NanoAbs while Apogee Therapeutics, Inc. uses conventional mAbs
- BiondVax NanoAbs provide superior benefits not seen in mAb therapies, including new routes of administration, higher affinity, better binding, and a higher level of stability at room temperature
- Apogee recently went public at $500 million pre-money, raising $300 million in an upsized deal, and has a $1 billion market cap – should be an eye-opener to BiondVax investors who recognize benefits of NanoAbs over mAb development
- The global psoriasis treatment market was valued at $26.13 billion in 2022 and is anticipated to reach $57.84 billion by 2031, growing at a CAGR of 9.23%
Modern-day medicine has been revolutionized and personalized to cater to more specific disease characteristics. A prime example of this innovation is monoclonal antibodies (“mAbs”) and nanosized antibodies (NanoAbs), therapeutic options that address diseases in ways other therapies cannot. Several companies are penetrating the market and a compelling comparison can be made between two – one supporting mAbs and the other NanoAbs. Both companies share similar objectives and stages of development.
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is focused on the development of NanoAbs derived from alpacas. Alpaca-derived antibodies, also called VHH-antibodies, exhibit the potential for superior biobetter therapies that could be used for a wide range of diseases. BiondVax’s current pipeline is targeting COVID-19, psoriasis, asthma, and other diseases with large unmet medical needs – with collaboration from the prestigious Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”), both in Germany.
Apogee Therapeutics (NASDAQ: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications, is focused on the development of conventional mAbs therapeutics (https://nnw.fm/azQRk ). The company’s technology approach has been shown to create antibodies with significantly extended half-life and other optimized properties. The primary enhancement that Apogee hopes to achieve through its mAb development is a slightly longer duration of benefit and slightly fewer drug administrations.
Despite the benefits that conventional mAbs offer, BiondVax’s NanoAbs may offer superior benefits that Apogee’s formulations cannot, such as:
The opportunity for new routes of administration, such as inhalation and intradermal injection – neither of which work well with traditional antibody therapies, thereby creating new market opportunities for BiondVax without competing head-to-head with existing antibody treatments
A higher affinity and better binding to the target, permitting lower dosages, fewer side effects, and lower costs overall
Stability at room temperature, unlike regular antibodies that need cold chain logistics until they are administered to the patient thus limiting where and when administration occurs
The potential benefits of BiondVax’s NanoAbs have been showcased in the company’s own pre-clinical studies, and the company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing.
Apogee and BiondVax are targeting the immune system’s IL-17 cytokine as they develop their drugs; IL-17 is involved in several diseases with BiondVax initially targeting IL-17 towards a psoriasis treatment.
The global psoriasis treatment market was valued at $26.13 billion in 2022 and is anticipated to reach $57.84 billion by 2031, growing at a CAGR of 9.23% (https://nnw.fm/w2FHQ ). The market is expected to grow at this rate due to the increased awareness of the affliction and the advancement in therapies associated with it. BiondVax’s VHH antibodies propose a different approach to treatment, which does not necessarily compete head-to-head with treatment options, but provides a unique alternative approach.
Apogee only recently went public a few weeks ago at $500 million pre-money, raising $300 million in an upsized deal, and now the company has a $1 billion market cap. BiondVax’s NanoAb advantages over Apogee’s mAbs offer an attractive prospect to investors who are looking to get in early on the “bio better” antibody movement. With huge potential and a market cap that’s currently miniscule in comparison, only about $5 million and trading under a $1.50 per share, its little wonder that Aegis Capital reiterated its buy rating with a $7 price target (https://nnw.fm/31MTL ).
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)